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Résumé en
anglais
BACKGROUND: A polymorphism (rs35705950) 3 kb upstream of MUC5B, the gene
encoding Mucin 5 subtype B, has been shown to be associated with familial and
sporadic idiopathic pulmonary fibrosis (IPF). We set out to verify whether this variant
is also a risk factor for fibrotic lung disease in other settings and to confirm the
published findings in a UK Caucasian IPF population. METHODS: Caucasian UK
healthy controls (n=416) and patients with IPF (n=110), sarcoidosis (n=180) and
systemic sclerosis (SSc) (n=440) were genotyped to test for association. The SSc and
sarcoidosis cohorts were subdivided according to the presence or absence of fibrotic
lung disease. To assess correlation with disease progression, time to decline in
forced vital capacity and/or lung carbon monoxide transfer factor was used in the IPF
and SSc groups, while a persistent decline at 4 years since baseline was evaluated in
patients with sarcoidosis. RESULTS: A significant association of the MUC5B
promoter single nucleotide polymorphism with IPF (p=2.04 x 10(-17); OR 4.90, 95%
CI 3.42 to 7.03) was confirmed in this UK population. The MUC5B variant was not a
risk factor for lung fibrosis in patients with SSc or sarcoidosis and did not predict
more rapidly progressive lung disease in any of the groups. Rather, a trend for a
longer time to decline in forced vital capacity was observed in patients with IPF.
CONCLUSIONS: We confirm the MUC5B variant association with IPF. We did not
observe an association with lung fibrosis in the context of SSc or sarcoidosis,
potentially highlighting fundamental differences in genetic susceptibility, although
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